Concord Biotech CONCORDBIO
Fermentation-based APIs - a global leader in immunosuppressants (mycophenolate, tacrolimus) and anti-infectives - moving into formulations
Mapped in 1 theme: Pharmaceuticals.
Where Concord Biotech sits in the supply chain
Concord Biotech appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › APIs (active ingredients)
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,017 | 1,200 | 1,055 |
| Net profit | 308 | 372 | 259 |
Latest-year revenue ₹1,055 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Fermentation know-how is a high entry barrier; historically ~40% EBITDA margins
- Debt-free
Risks
- FY26 revenue fell 12% and profit 30% on pricing and customer destocking
- Concentration in immunosuppressant molecules
Common questions
What does Concord Biotech do?
Fermentation-based APIs - a global leader in immunosuppressants (mycophenolate, tacrolimus) and anti-infectives - moving into formulations.
Where does Concord Biotech sit in the supply chain?
Concord Biotech (NSE: CONCORDBIO) is mapped in 1 supply-chain layer: APIs (active ingredients) (Pharmaceuticals).
Who are Concord Biotech's peers?
In the APIs (active ingredients) layer of Pharmaceuticals: Divi's Laboratories, Laurus Labs, Aarti Drugs, Solara Active Pharma Sciences, Granules India, Neuland Laboratories and 2 more.
What is Concord Biotech's market cap and valuation?
As of 30 Oct 2026: market cap ₹13,038 Cr, P/E 45.8x, ROCE 17.1%, ROE 12.5%, dividend yield 0.30%.